NLRP3 inflammasome in metabolic syndrome
Braz. J. Pharm. Sci. (Online)
;
56: e18968, 2020.
Article
Dans Anglais
| LILACS
| ID: biblio-1249173
ABSTRACT
Metabolic syndrome (MS) is a serious health problem worldwide; it is characterized by a group of metabolic disorders, including central obesity, insulin resistance/type 2 diabetes, hyperlipidemia with accelerated atherosclerosis, hypertension, non-alcoholic fatty liver disease, and elevated uric acid with increased risk of gout. The incidence of MS has increased considerably in recent decades and has attracted considerable attention. A number of clinical and translational laboratory studies have implicated the activation of nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome in the development of MS, therefore establishing a strong link between chronic inflammation and metabolic diseases. This paper aims to review new developments on NLRP3 inflammasome in MS for better understanding of chronic inflammation in metabolic diseases. We will also provide new insights into using NLRP3 inflammasome as an innovative therapeutic target.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Inflammasomes
/
Maladies métaboliques
langue:
Anglais
Texte intégral:
Braz. J. Pharm. Sci. (Online)
Thème du journal:
Farmacologia
/
Teraputica
/
Toxicologia
Année:
2020
Type:
Article
Pays d'affiliation:
Chine
Institution/Pays d'affiliation:
Central South University/CN
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS